WJWang Jia

Wang Jia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wang Jia has a total of 64 co-authors. Here are the top co-authors by number of shared publications:

  • Dainan Zhang

    Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

    7 shared publications
  • Shunchang Ma

    Department of Neurosurgery, Beijing Tian Hospital, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China

    5 shared publications
  • Shaomin Li

    Henan Key Laboratory of Neurorestoratology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, China

    4 shared publications
  • Xi Wang

    Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China; Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China

    4 shared publications
  • Beibei Mao

    Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

    2 shared publications
  • Chaowei Zou

    Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China

    2 shared publications

Latest Publications

  • Open Access

    Author Correction: A proteogenomic atlas of 1032 brain metastases identifies molecular subtypes, immune landscapes, and therapeutic vulnerabilities

    by Zhenyu Yang, Shiyou Wei, Hao Duan, Xiuqi Wang, Dainan Zhang, Karrie Mei-Yee Kiang, Yulan Deng, Yuanzhong Yang, Yin Ku, Wanming Hu, et al.


  • Open Access

    A proteogenomic atlas of 1032 brain metastases identifies molecular subtypes, immune landscapes, and therapeutic vulnerabilities

    by Zhenyu Yang, Shiyou Wei, Hao Duan, Xiuqi Wang, Dainan Zhang, Karrie Mei-Yee Kiang, Yulan Deng, Yuanzhong Yang, Yin Ku, Wanming Hu, et al.

    The molecular heterogeneity of brain metastases hampers therapeutic development for cures. To address this unmet and urgent need, we construct a comprehensive multi-omic, single cell, and spatially resolved atlas of 1,032 pan-cancer brain metastases, identifying four robust molecular subtypes with distinct biological programs and clinical associations. These brain metastases subtypes (BrMS) are defined by unique biological states: neural-like (BrMS1), metabolic (BrMS3), highly proliferative/immune-excluded (BrMS4), and an immune-infiltrated (BrMS2) state featuring a coordinated epithelial-mesenchymal transition program. Patient-derived organoids coupled with targeted drug screening indicate subtype-specific molecular dependencies and putative targets, notably mTOR signaling activation in BrMS3 and CDK4/6 axis activation in BrMS4, while BrMS1 and BrMS2 display distinct radiobiologic and immunologic signatures. This atlas provides a rigorous classification framework of BrMs and offers insights into subtype-specific molecular vulnerabilities.


  • Open Access

    PLEKHA4 is transcriptionally regulated by HOXD9 and regulates glycolytic reprogramming and progression in glioblastoma via activation of the STAT3/SOCS-1 pathway

    by Dainan Zhang, Xiaoyin Wang, Meng Xiao, Shunchang Ma, Shaomin Li, Wang Jia

    Recent studies have demonstrated that PLEKHA4 promotes tumor growth in some cancers, such as small-cell lung cancer, melanoma, and hepatic carcinomas; however, the underlying mechanism in glioblastoma remains ambiguous. Bioinformatic was used to analysis PLEKHA4 expression. In vitro and in vivo experiments were conducted to detect the effect of PLEKHA4 on glioblastoma cell glycolytic reprogramming and progression. GSEA was used to analyze the signal pathways related to PLEKHA4. Pharmacological methods further validated the role of activation pathways. We evaluated the effects of PLEKHA4 knockdown combined with temozolomide (TMZ) on glioblastoma cell proliferation and apoptosis in vitro and in vivo. We observed an overexpression of PLEKHA4 in GBM cell lines, resulting in enhanced cell proliferation, inhibited apoptosis, and promoted glycolysis. Mechanistically, our study demonstrated that PLEKHA4 mediates cell proliferation, apoptosis, and glycolysis via the STAT3/SOCS1 signaling pathway. Additionally, HOXD9 was predicted using Jasper, which is a transcription factor that binds to the PLEKHA4 promoter region. Knocking down PLEKHA4 combined with TMZ inhibited cell proliferation and promoted cell apoptosis in vitro and in vivo. Our results indicated that HOXD9-medicated PLEKHA4 regulates glioblastoma cell proliferation and glycolysis via activation of the STAT3/SOCS1 pathway.


  • Integrated proteomic and glycoproteomic analysis reveals heterogeneity and molecular signatures of brain metastases from lung adenocarcinomas

    by Yang Zhao, Dainan Zhang, Bo Meng, Yong Zhang, Shunchang Ma, Jiaming Zeng, Xi Wang, Tao Peng, Xiaoyun Gong, Rui Zhai, et al.


  • Open Access

    Bioinformatics analysis of the prognostic value of NEK8 and its effects on immune cell infiltration in glioma

    by Meng Xiao, Chaoyang Du, Chuanbo Zhang, Xinzhong Zhang, Shaomin Li, Dainan Zhang, Wang Jia

    Glioma is the most common malignancy of the nervous system with high rates of recurrence and mortality, even after surgery. The 5‐year survival rate is only about 5%. NEK8 is involved in multiple biological processes in a variety of cancers; however, its role in glioma is still not clear. In the current study, we evaluated the prognostic value of NEK8, as well as its role in the pathogenesis of glioma. Using a bioinformatics approach and RNA‐seq data from public databases, we found that NEK8 expression is elevated in glioma tissues; we further verified this result by RT‐PCR, Western blotting and immunochemistry using clinical samples. Functional enrichment analyses of genes with correlated expression indicated that elevated NEK8 expression is associated with increased immune cell infiltration in glioma and may affect the tumour microenvironment via the regulation of DNA damage/repair. Survival analyses revealed that high levels of NEK8 are associated with a poorer prognosis; higher WHO grade, IDH status, 1p/19q codeletion, age and NEK8 were identified as an independent prognostic factor. These findings support the crucial role of NEK8 in the progression of glioma via effects on immune cell infiltration and suggest that it is a new prognostic biomarker.


  • Retracted
    Open Access

    RETRACTED: MicroRNA-935 Directly Targets FZD6 to Inhibit the Proliferation of Human Glioblastoma and Correlate to Glioma Malignancy and Prognosis

    by Dainan Zhang, Shunchang Ma, Chuanbao Zhang, Peiliang Li, Beibei Mao, Xiudong Guan, Wenjianlong Zhou, Jiayi Peng, Xi Wang, Shaomin Li, et al.

    MicroRNAs (miRNAs) are involved in human glioblastoma (GB). MiR-935 has been reported to have both tumor-inhibiting and tumorigenesis effects, but its role in GB remains unclear. Because of the high mortality and morbidity associated with the malignancy of GB, a deeper understanding of the molecular crosstalk that occurs in GB is needed to identify new potential targets for treatment. At present, the mechanism of GB at the molecular level is not fully understood. With the aid of bioinformatic analysis, miR-935 was significantly downregulated in GB, and it presented a poorer outcome. In the glioma cell line and in the nude mice model, the miR-935 inhibited cell proliferation by modulating cell circles in vitro and in vivo . Then, the target genes of miR-935 were analyzed by using the online database, and the direct binding was tested with a luciferase analysis. FZD6 was found to be the direct target of miR-935. The effect of miR-935 was recovered by the overexpression of FZD6 in vitro . In addition, the negative correlation of miR-935 and the expression of FZD6 were confirmed in our clinical samples, and the expression of FZD6 has a strong correlation with tumor malignancy and prognosis. This study showed that miR-935 directly inhibited the expression of FZD6 and inhibited the cell proliferation, thereby suppressing the development of GB, suggesting that miR-935 is a cancer suppressor miRNA and may become a prognostic biomarker or a promising potential therapeutic target for human GBs.


  • Open Access

    Cpne3 Regulates the Cell Proliferation and Apoptosis in Human Gbm via the Activation of Pi3k/akt Signaling Pathway

    by Dainan Zhang, Xiaoyin Wang, Xi Wang, Zemin Wang, Shunchang Ma, Chuanbao Zhang, Shaomin Li, Wang Jia

    Background: Even with decades of intensive study, the signaling regulative network of the progression of GBM remains unclear, a deeper understanding of the molecular crosstalk with pathways in GBM is needed to identify new potential targets for treatment. Methods: To investigated the expression of CPNE3 in GBM, we applied bioinformatic analysis and clinical samples validation. Then the functional validation of carried out in commercially available glioma cell lines and nude mice model. Also, the GSEA analysis was used to identify the relevant pathways. The role of activated pathway was further validated by pharmacology method.Results: We found that CPNE3 was significantly up-regulated in GBM when compared with adjacent normal tissues, and the overexpression of CPNE3 promoted cell proliferation and inhibiting cell apoptosis in vitro and in vivo. Also, the principal protein markers of PI3K/AKT pathway were found to be phosphorylated by CPNE3 over-expression, and pathway inhibitor, LY294002, alleviated the cell proliferation enhancement induced by CPNE3 over-expression. Conclusion: Our results showed that the expression of CPNE3 promotes cell proliferation by inhibiting cell apoptosis via activating PI3K/AKT pathway, thereby enhancing the progression of GBM, which suggesting that CPNE3 may play as a tumorigenesis gene and its crosstalk with PI3K/AKT pathway may become a promising potential therapeutic target for human GBMs.

  • Targeted exome sequencing for the identification of common mutational signatures and potential driver mutations for brain metastases and prognosis

    by Dainan Zhang, Xi Wang, Shunchang Ma, Peiliang Li, Fei Xue, Beibei Mao, Xiudong Guan, Wenjianlong Zhou, Jiayi Peng, Kun Su, et al.

    Brain metastases (BMs) are malignancies in the central nervous system with poor prognosis. Genetic landscapes of the primary tumor sites have been extensively profiled; however, mutations associated with BMs are poorly understood. In the present study, target exome sequencing of 560 cancer-associated genes in samples from 52 patients with brain metastasis from various primary sites was performed. Recurrent mutations for BMs from distinct origins were identified. There were both genetic homogeneity and heterogeneity between BMs and primary lung tumor tissues. The mutation rate of the major cancer driver gene, TP53, was consistently high in both the primary lung cancer sites and BMs, while some genetic alterations, associated with DNA damage response deficiency, were specifically enriched in BMs. The mutational signatures enriched in BMs could serve as actionable targets for treatment. The mutation in the primary site of the potential brain metastasis driver gene, nuclear mitotic apparatus protein 1 (NUMA1), affected the progression-free survival time of patients with lung cancer, and patients with the NUMA1 mutation in BMs had a good prognosis. This suggested that the occurrence and clinical outcome of brain metastases could be independent of each other.

  • Blood-Based Glutamate Scavengers Reverse Traumatic Brain Injury-Induced Synaptic Plasticity Disruption by Decreasing Glutamate Level in Hippocampus Interstitial Fluid, but Not Cerebral Spinal Fluid, In Vivo

    by Dainan Zhang, Meng Xiao, Long Wang, Wang Jia

    Excessive glutamate release has been implicated as a major contributor to multiple post-traumatic brain injury (TBI) deficits, including neurodegeneration and cognitive impairment. Prior to the presence of behavior change, synaptic plasticity is rapidly and potently disrupted by TBI, which is believed to be relevant to inappropriately increased extracellular glutamate concentration and glutamatergic receptor activation. Acutely promoting brain glutamate clearance with a blood-based scavenging system, glutamate oxaloacetate transaminase (GOT), prevents the delayed inhibition of LTP post-TBI. Here, we report that repeated dosing of recombinant GOT type 1, with the glutamate co-substrate oxaloacetate, could induce a persistent enhancement of serum level of GOT and reverse the disruption of synaptic plasticity 4 days after the induction of TBI in rats. Moreover, the change of glutamate level post-TBI presents a different timeframe in ventricular CSF and hippocampus interstitial fluid (ISF), and the application of rGOT may reverse the inhibition of LTP by decreasing the glutamate level in hippocampus ISF, but not ventricular CSF. Lastly, we found that the intervention did not significantly affect the total level of glutamate in the hippocampus as well as the expression of major glutamate transporters, EAAT1 and EAAT2. Overall, the present findings support the importance of clearance of glutamate post-TBI and provide new evidence of the mechanism of glutamate-induced LTP inhibition which leads to a development of evaluations, intervention, and reversion for post-TBI cognitive deficit.


  • Primary Intracranial Angioleiomyomas as Rare, Nonmalignant, and Distinct Neoplastic Entities: A Series of 8 Cases and a Literature Review

    by Cheng-Bei Li, Ming-Guo Xie, Jun-Peng Ma, Liang Wang, Shu-Yu Hao, Li-Wei Zhang, Wang Jia, Gui-Jun Jia, Jun-Ting Zhang, Da Li, et al.